Patents by Inventor Magnus Strandh

Magnus Strandh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10570192
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: February 25, 2020
    Assignee: Genentech, Inc.
    Inventors: Eric J. Brown, Martine Darwish, John Flygare, Wouter Hazenbos, Byoung Chul Lee, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Publication number: 20180344846
    Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.
    Type: Application
    Filed: August 8, 2018
    Publication date: December 6, 2018
    Applicant: Symphogen A/S
    Inventors: Johan Lantto, Kim Vilbour Andersen, Peter Sejer Andersen, Magnus Strandh, Klaus Koefoed, Lars Søgaard Nielsen, Mikkel Wandahl Pedersen, Helle Jacobsen, Michael Kragh, Ida Kjaer, Thomas Tuxen Poulsen
  • Patent number: 10058610
    Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: August 28, 2018
    Assignee: Symphogen A/S
    Inventors: Johan Lantto, Kim Vilbour Andersen, Peter Sejer Andersen, Magnus Strandh, Klaus Koefoed, Lars Søgaard Nielsen, Mikkel Wandahl Pedersen, Helle Jacobsen, Michael Kragh, Ida Kjaer, Thomas Tuxen Poulsen
  • Publication number: 20180085470
    Abstract: The invention provides anti-wall teichoic acid antibodies, antibiotic-linker intermediates, and antibody-antibiotic conjugate compound, and methods of making and using the same.
    Type: Application
    Filed: December 7, 2017
    Publication date: March 29, 2018
    Applicant: Genentech, Inc.
    Inventors: Eric J. Brown, John Flygare, Wouter Hazenbos, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Patent number: 9895450
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: February 20, 2018
    Assignee: Genentech, Inc.
    Inventors: Eric J. Brown, John Flygare, Wouter Hazenbos, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Patent number: 9884126
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: February 6, 2018
    Assignee: Genentech, Inc.
    Inventors: Eric J. Brown, John Flygare, Wouter Hazenbos, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Publication number: 20180016325
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Application
    Filed: September 28, 2017
    Publication date: January 18, 2018
    Applicant: Genentech, Inc.
    Inventors: Eric J. Brown, Martine Darwish, John Flygare, Wouter Hazenbos, Byoung Chul Lee, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Patent number: 9803002
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: October 31, 2017
    Assignee: Genentench, Inc.
    Inventors: Eric J. Brown, Martine Darwish, John Flygare, Wouter Hazenbos, Byoung Chul Lee, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Publication number: 20170165365
    Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.
    Type: Application
    Filed: November 14, 2016
    Publication date: June 15, 2017
    Inventors: Johan Lantto, Kim Vilbour Andersen, Peter Sejer Andersen, Magnus Strandh, Klaus Koefoed, Lars Søgaard Nielsen, Mikkel Wandahl Pedersen, Helle Jacobsen, Michael Kragh, Ida Kjaer, Thomas Tuxen Poulsen
  • Patent number: 9527913
    Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: December 27, 2016
    Assignee: SYMPHOGEN A/S
    Inventors: Johan Lantto, Kim Vilbour Andersen, Peter Sejer Andersen, Magnus Strandh, Klaus Koefoed, Lars Søgaard Nielsen, Mikkel Wandahl Pedersen, Helle Jacobsen, Michael Kragh, Ida Kjær, Thomas Tuxen Poulsen
  • Publication number: 20160074529
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Application
    Filed: November 19, 2015
    Publication date: March 17, 2016
    Applicant: GENENTECH, INC.
    Inventors: Eric J. Brown, John Flygare, Wouter Hazenbos, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Publication number: 20150366985
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Application
    Filed: May 22, 2014
    Publication date: December 24, 2015
    Applicant: GENENTECH, INC.
    Inventors: Eric J. Brown, John Flygare, Wouter Hazenbos, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Publication number: 20150086478
    Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.
    Type: Application
    Filed: May 2, 2013
    Publication date: March 26, 2015
    Inventors: Johan Lantto, Kim Vilbour Andersen, Peter Sejr Andersen, Magnus Strandh, Klaus Koefoed, Lars Søgaard Nielsen, Mikkel Wandahl Pedersen, Helle Jacobsen, Michael Kragh, Ida Kjær, Thomas Tuxen Poulsen
  • Publication number: 20140356375
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Application
    Filed: May 22, 2014
    Publication date: December 4, 2014
    Applicant: GENENTECH, INC.
    Inventors: Eric J. Brown, Martine Darwish, John Flygare, Wouter Hazenbos, Byoung Chul Lee, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Publication number: 20140356376
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Application
    Filed: May 30, 2014
    Publication date: December 4, 2014
    Applicant: GENENTECH, INC.
    Inventors: Eric J. Brown, Martine Darwish, John Flygare, Wouter Hazenbos, Byoung Chul Lee, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Publication number: 20040185467
    Abstract: Improved methods using microscope based detection for identifying nucleic acid polymorphisms rely on localizing the region to be tested using particulate labels. The length of a segment containing tandem repeats can be determined by the intensity of signal emitted by a fluorophore associated with the repeat and bracketed by the labels; the presence of an allele containing a restriction site can be identified by viewing the association or dissociation of particulate labels. Single nucleotide polymorphisms characterized by the presence or absence of a referent base can be detected with a large differential in binding energy using short probes, by virtue of localizing the base to be interrogated with flanking particulate labels. The methods may be performed on a multiplicity of test nucleic acids simultaneously by employing a multiplicity of particulate labels with differing hues.
    Type: Application
    Filed: November 13, 2003
    Publication date: September 23, 2004
    Inventors: Lawrence M. Kauvar, Magnus Strandh, Remy Cromer